# SMS Pharmaceuticals share price today (SMS Pharmaceuticals Ltd, NSE: SMSPHARMA) > SMS Pharmaceuticals share price today: ₹476.80 at the NSE close on 18 November 2026, up 69.1% in a year. SMS Pharmaceuticals (NSE: SMSPHARMA) is worth ₹4,466 crore, trades at a P/E of 38.2 and has closed between ₹281.90 and ₹516.70 over the past 52 weeks. > SMS Pharmaceuticals Ltd's share price has risen faster than its earnings: +69.1% in a year, against +39.6% for earnings per share. SMSPHARMA · Pharma - API & CRAMS · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Growing steadily, from the last 12 quarters - Price: ₹476.80 (+69.1% in a year) - P/E: 38.2× (higher than 86% of the last 11 years) - Revenue (Sep 2026): ₹316 Cr (+30.6% on a year ago) - Profit (Sep 2026): ₹40.0 Cr (+60.0% on a year ago) - Operating margin: 21.5% (+1.7 points on a year ago) - ROCE: 13%, FY26 - ROIC: 10.6%, against a 12.0% cost of capital: −1.4 points The main question: the share price moved +69.1% in a year while yearly earnings per share moved +39.6%. The difference came from the market paying a higher multiple. ## What is the SMS Pharmaceuticals share price today? SMS Pharmaceuticals Ltd's share price was ₹476.80 at the close on 18 November 2026. It has been rising for 61 weeks. That is 19.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹282 and ₹517, and at that close it sat 83% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 14 weeks in a row. Over the last 11 years the share price moved +608% while the NIFTY 500 moved +306%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at SMS Pharmaceuticals this quarter? Three changes stood out: profit up on a year earlier for 12 quarters in a row (every quarter we can compare), indian funds and insurers (DIIs) cut their stake for 3 quarters in a row and highest quarterly profit in 16 quarters. 1. Profit up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter profit was ₹40 crore, +60% on a year earlier. 2. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row From 3.2% to 0.2% of the company by the September 2026 quarter. 3. Highest quarterly profit in 16 quarters Profit of ₹40 crore in the September 2026 quarter is the highest of the last 16 quarters. ## What are SMS Pharmaceuticals' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), SMS Pharmaceuticals reported revenue of ₹316 crore, up 30.6% from ₹242 crore a year earlier, and a profit of ₹40.0 crore, up 60.0% from ₹25.0 crore. ### SMS Pharmaceuticals results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹316 crore | ₹242 crore | +30.6% | | Profit | ₹40.0 crore | ₹25.0 crore | +60.0% | | Earnings per share | ₹4.26 | ₹2.70 | +57.8% | | Operating margin | 21.5% | 19.8% | +1.7 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). SMS Pharmaceuticals' management discussed these results on a call held on 5 November 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the SMS Pharmaceuticals share price history? SMS Pharmaceuticals closed at ₹476.80 on 18 November 2026, up 69.1% from ₹281.90 a year earlier (21 November 2025) and up 260.8% over five years. Its highest weekly close since February 2016 was ₹511.35 on 30 October 2026. ### SMS Pharmaceuticals share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹523.55 | −8.9% | | 1 month ago · 19 Oct 2026 | ₹434.65 | +9.7% | | 6 months ago · 15 May 2026 | ₹400.40 | +19.1% | | 1 year ago · 21 Nov 2025 | ₹281.90 | +69.1% | | 3 years ago · 17 Nov 2023 | ₹118.20 | +303.4% | | 5 years ago · 18 Nov 2021 | ₹132.15 | +260.8% | | 10 years ago · 18 Nov 2016 | ₹77.91 | +512.0% | | Earliest weekly close in our records · 26 Feb 2016 | ₹67.37 | +607.7% | | Highest weekly close since February 2016 · 30 Oct 2026 | ₹511.35 | −6.8% | | Lowest weekly close since February 2016 · 27 Mar 2020 | ₹26.10 | +1,726.8% | | 52-week high (weekly close) · 5 Nov 2026 | ₹516.70 | −7.7% | | 52-week low (weekly close) · 21 Nov 2025 | ₹281.90 | +69.1% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (568 weekly closes from 26 February 2016 to 18 November 2026.) ## What is the latest news on SMS Pharmaceuticals? 18 Nov 2026: SMS Pharmaceuticals closed at ₹476.80, down 8.9% on the week and up 9.7% on the month. 5 Nov 2026: SMS Pharmaceuticals held its results call for July to September 2026. Management guided: FY27 revenue growth and operating margin to exceed 15% and 20% respectively. ### Earlier - Results for July to September 2026: Revenue up 30.6% and profit up 60.0% on a year earlier. - 22 Sep 2026: ex-date for a dividend of ₹0.40 a share. ## What dividend does SMS Pharmaceuticals pay? SMS Pharmaceuticals paid ₹0.40 a share in regular dividends in the 12 months to 18 November 2026 (1 payment), a yield of 0.08% at the ₹476.80 close on 18 November 2026. The last was a dividend of ₹0.40 a share, ex-date 22 September 2026. ### SMS Pharmaceuticals dividends since 1 April 2021 | Ex-date | Dividend per share | Type | Record date | | --- | --- | --- | --- | | 22 Sep 2026 | ₹0.40 | Dividend | same day | | 22 Sep 2025 | ₹0.40 | Dividend | same day | | 23 Sep 2024 | ₹0.40 | Dividend | same day | | 22 Sep 2023 | ₹0.30 | Dividend | same day | | 22 Sep 2022 | ₹0.30 | Dividend | 23 Sep 2022 | | 22 Sep 2021 | ₹0.30 | Dividend | n/a | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record Yes. SMS Pharmaceuticals Ltd paid out 4% of its profit as dividends in FY26, and it paid a dividend in 13 of its last 14 reported years. One of those years shows a negative figure because profit itself was negative. (From the NSE corporate-actions record, read 18 November 2026.) ## What did SMS Pharmaceuticals management say on the latest results call? On the call for July to September 2026, held on 5 November 2026, SMS Pharmaceuticals' management guided: FY27 revenue growth and operating margin to exceed 15% and 20% respectively. > “Backward integration gives us a structural cost advantage, not a temporary pricing benefit, and this quarter shows that clearly.” > Vamsi Krishna Potluri, on the call for July to September 2026 ### What management guided - Next-year operating margin planned 22-24% on high-value commercialization and operating leverage. - 6-8 new molecules to start commercial production in FY28 scaling over following 6 quarters operating profit-accretive. - Ibuprofen capacity to 9,600 tons in coming 1-2 quarters with ramp to about 90% occupancy over 6-9 months. - Peptide pilot scale in January to March 2027 with first CRO revenue in July to September 2027 on own generics and service ramp. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/4701/Conference Call/CC-Nov26.pdf). (From the call for July to September 2026, 5 November 2026.) ## What to watch in SMS Pharmaceuticals' next results? When SMS Pharmaceuticals reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Ibuprofen expansion completion and ramp toward flagged occupancy - confirm reactors capitalized and volume run-rate stepped up. Management raised each of these on the latest results call. - Ibuprofen expansion completion and ramp toward flagged occupancy - confirm reactors capitalized and volume run-rate stepped up. - Peptide pilot readiness and shift toward first revenue milestone - confirm samples issued and customer discussions commenced. - Durability of volume plus realization run-rate through H2 to uphold raised yearly framework and next-year margin path. ## Which stock lists is SMS Pharmaceuticals on? SMS Pharmaceuticals is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market value: ₹4,563 crore](https://www.sectoralpha.in/momentum-stocks-india) - [Pharma stocks Market value: ₹4,563 crore](https://www.sectoralpha.in/sectors/pharma-stocks-india) ## Is SMS Pharmaceuticals profitable? SMS Pharmaceuticals Ltd earned ₹40.0 Cr of net profit in the Sep 2026 quarter, +60.0% on the same quarter a year earlier. That is the 12th quarter in a row of profit growth. Full-year FY26 profit was ₹102 Cr. Over 10 years profit has grown 9.5% a year on average. The same quarter a year earlier earned ₹25.0 Cr. The Sep 2026 quarter's profit is 12.7% of that quarter's revenue. For the full year, FY26 profit was ₹102 Cr (+47.8% on the year before). Why profit moved: revenue changed +30.6% on a year earlier and the margin moved +1.7 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +39.5% and revenue +13.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does SMS Pharmaceuticals make, and is it growing? SMS Pharmaceuticals Ltd reported ₹316 Cr of revenue in the Sep 2026 quarter, +30.6% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown 3.8% a year on average. The last full year, FY26, came in at ₹887 Cr. The last four reported quarters add to ₹971 Cr. FY26 revenue was ₹887 Cr, +13.3% on the year before. Recent pace: the last four quarters grew +13.4% on average, against 3.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +13.0%, against +12.4% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +41.0%, against +42.0% a year (stabilising). ## How much of every ₹100 of sales does SMS Pharmaceuticals keep? SMS Pharmaceuticals Ltd's operating margin was 21.5% in the Sep 2026 quarter, 1.7 percentage points higher than the same quarter a year ago. Across 14 years it has been between 10.5% and 24.4%. The latest quarter is within that range. Why this happened. Management attributes part of the earlier gross-margin improvement to backward integration and describes its protection during input inflation. This is a delivered cost mechanism, not evidence that every future cost saving will remain with shareholders. The latest quarterly operating margin is unchanged year on year. Competitive price reductions could pass savings to customers, while financing and depreciation absorb part of incremental operating profit. Integration, volume and utilization are dependent links in this driver and are not additive profit estimates. Why the margin moved: operating margin changed +1.5 percentage points on the year while gross margin changed −0.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is SMS Pharmaceuticals' profit turning into cash? Over the last 3 years, 86% of SMS Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹59.0 Cr of operating cash against ₹102 Cr of profit. After ₹131 Cr of spending on assets, free cash was −₹72.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 86% of profit came in as cash: the cash cycle got 114 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 2.9× depreciation over three years. The next section checks what that spending is building. ## Where does SMS Pharmaceuticals' cash go? SMS Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 260 days in FY26, up from 146 days in FY21. It spent ₹306 Cr on assets over the last 3 years. Customers take 89 days to pay, and stock sits for 260 days on average. At FY26 sales of ₹887 Cr, each day of that cycle ties up about ₹2.4 Cr, so roughly ₹632 Cr is tied up in the business at any time. FY26: customers took 89 days to pay and stock sat for 260 days, about 8.6 months of sales sitting as stock, for a full cycle of 260 days, longer than FY21's 146. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 260 days. Customers pay about 89 days after that. Suppliers are paid at 89 days. Together that makes the 260-day cycle. Spending on assets: ₹306 Cr over the last 3 years, against ₹106 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹122 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is SMS Pharmaceuticals' P/E ratio, and how does it compare with its own history? SMS Pharmaceuticals Ltd's P/E is 38.2×, near the high end of its own history: higher than 86% of past readings. Its usual P/E (the middle reading) is 24.1×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +39.6% while the price moved +69.1%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +29.3% a year; about +3.0% a year came from earnings growth and about +26.3 percentage points from the multiple (the market paying more); over 10 years the price moved +19.9% a year; about +9.9% a year came from earnings growth and about +10.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the SMS Pharmaceuticals share price assume? Worked out from its price on 11 October 2026, SMS Pharmaceuticals Ltd's share price assumed profit growth of about 24.5% a year. Over the past 10 years its profit actually grew 9.5% a year. Today its P/E is 38.2×, higher than 86% of its own last 11 years. This is a one-day reading, taken on 11 October 2026. Every other number on this page, the multiple included, uses the latest price as of 18 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the SMS Pharmaceuticals business getting better or worse? SMS Pharmaceuticals Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 16.5% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures. Why it matters: steady growth with healthy returns is how a business compounds over time. ## What is the SMS Pharmaceuticals story, and has it been checked? SMS Pharmaceuticals Ltd's story is not scored yet against the checks our research set on 10 October 2026. Where it sits in its own cycle: mid expansion. What is proven. See the research file What is not proven yet. I would abandon the operating-recovery thesis if the expanded Ibuprofen line is commissioned but subsequent results show declining operating profit and further inventory accumulation, with management unable to reconcile customer demand to collections. The test written in advance. The test written in advance. Inventory funding and order-quality uncertainty. Measured by: Inventory funding and order-quality uncertainty Inventory days rise again while operating cash conversion fails to recover. by the next result. What the company does. Reported earnings improved, but the latest quarter slowed and the preceding quarter included a material associate contribution. Ibuprofen expansion and new APIs provide dated forward fuel, while revenue guidance misses, commissioning delays and inventory absorption limit confidence. What the surface reading misses. What the surface reading misses. The surface reading is: Annual PAT rose faster than sales, suggesting an earnings acceleration. The research reads it further: Operating profit also increased, but the latest summary identifies associate earnings within reported PAT. The operating recovery is real and smaller than the headline PAT growth. Lever 1 · Operating leverage: building. In-house intermediates protect Ibuprofen economics, but retained profits depend on realised prices after solvent and financing costs. What proves it keeps working: Backward integration and retained margins. Lever 2 · Value-added mix: building. Dated capacity additions provide forward fuel, with commissioning preceding customer validation, sales and cash collection. What proves it keeps working: Ibuprofen capacity and new API commissioning. It stops working if Commissioning slips again or commissioned capacity lacks validated customer orders. Lever 5 · Regulatory approval: building. Capability building creates later options; no near-term earnings credit is assigned without commercial evidence. What proves it keeps working: Peptides and CDMO options. It stops working if Capability updates fail to progress to customer qualification and commercial contracts. Sources: our stock research file (10 October 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did SMS Pharmaceuticals management deliver what it promised? What SMS Pharmaceuticals Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Peptide Commercialization Timeline Moved Forward Without Explanation · 5 November 2026. The May 2026 call said meaningful peptide contributions were expected from FY29, and the Nov 2025 call planned commercial operations for FY '29. The Nov 2026 call now goals commercial production in Q4 FY27 and first CRO revenue in Q2 FY28, a material acceleration that management did not explain. Peptide R&D Readiness Is Less Advanced Than Previously Described · 5 November 2026. In May 2026, management described an established peptide R&D effort with promising initial results and multiple products underway. In Nov 2026, it said R&D had started only a couple of months earlier and that no samples had been sent, without explaining whether the latest comments refer to a narrower program; this creates a material inconsistency in the evidence supporting the peptide growth thesis. Capex Program Size Is Internally Unresolved · 5 November 2026. The May 2026 and Nov 2025 calls described an INR280 crore capex program. In Nov 2026, the prepared remarks refer to a 180 crore program, while the Q&A returns to a 280 crore total and implies 120 crores remain; management did not reconcile the difference, which matters for funding and debt assumptions. Revenue Growth Guidance Cut · 27 May 2026. In both the Jun 2025 and Nov 2025 calls, management strongly guided for 20% revenue growth for the year. However, in the May 2026 call, management abandoned this 20% goal after delivering only 13% total growth for FY26, and structurally lowered their forward-looking guidance to 15% for FY27, citing external supply chain uncertainties. Every quote above is taken word for word from the company’s own earnings calls. ## What is SMS Pharmaceuticals management's track record? SMS Pharmaceuticals management consistently guides for 20% annual revenue growth and 20% operating margin. While FY25 was a transition year with a miss (10% revenue growth and 18% operating margin vs. 20% goals), execution in FY26 has been exceptionally precise. In April to June 2025, the company met goals with 19% revenue growth and 20% operating profit. July to September 2025 saw a beat with 23.1% revenue growth and ~20% operating profit. Most recently, October to December 2025 results showed 21% revenue growth and 21% operating margin, exceeding guidance. Management has reaffirmed the 20% growth outlook for the full year FY26, driven by backward integration and ramp-up in the anti-diabetic and ibuprofen segments. ### Regulatory and governance record SMS Pharmaceuticals (SMSPHARMA) faced minor regulatory actions in 2025-2026. In March 2025, BSE and NSE imposed fines of ₹2,000 per day for non-compliance with SEBI LODR Regulation 19(1)(c) regarding the composition of its Nomination and Remuneration Committee; the company corrected this technical oversight. In March 2026, the firm received a ₹7.19 crore income tax demand for AY 2018-19 for alleged under-reporting of income, which it is currently reviewing. USFDA inspections in 2025 were largely positive, with a 'No Action Indicated' (NAI) status for its Hyderabad lab and one minor observation for its Vizag facility. A 2025 drug racket involving 'PNM Life Sciences' is unrelated to the company despite the similar name. (Checked 12 April 2026.) ## How much does SMS Pharmaceuticals earn on its capital? SMS Pharmaceuticals Ltd earned a ROCE of 13% in FY26. That is up from a low of 4% in FY23. Its return on capital used (ROIC) is 1.4 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 11.5% net margin and 0.65× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 11.5% net margin × 0.65× asset turnover × 1.74× leverage (assets divided by equity) ≈ 13.0% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 10.6% − 12.0% = −1.4 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does SMS Pharmaceuticals have too much debt? SMS Pharmaceuticals Ltd has total debt of ₹349 Cr against shareholder equity of ₹842 Cr as of Sep 2026, so its debt is 0.41× its equity. Year by year, that ratio went from 0.56 in FY22 to 0.46 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the SMS Pharmaceuticals shareholding pattern? Promoters raised their stake in SMS Pharmaceuticals Ltd by 3.4 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 68.1% of the company. Domestic institutions moved −2.4 points over the same period, to 0.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +3.4 points over 8 quarters, to 68.1%; Domestic institutions: −2.4 points over 8 quarters, to 0.2%; Foreign institutions: +0.7 points over 8 quarters, to 1.2%. Why the owners changed: promoters drove it (+3.4 points), with the other side taken by domestic institutions (−2.4 points). They raised their stake step by step. ## How far is SMS Pharmaceuticals from balance-sheet trouble? For SMS Pharmaceuticals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. Why this happened. Generic-to-Specialty Value Migration is a possible direction, not a completed transition. The latest summary places meaningful peptide contribution beyond the current forecast period and promises further CDMO information. Development success, customer contracts, qualification costs and commercial margins remain unknown. These initiatives therefore support optionality rather than the base operating forecast. ## How does SMS Pharmaceuticals rank in its industry? 56.0 out of 100, rank 10 of 24 in Pharma - API & CRAMS, with 90% of the evidence available. SMS Pharmaceuticals Ltd scores 56.0 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 10. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 20.5 + 11.9 + 8.3 + 15.3 = 56. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is SMS Pharmaceuticals compared with? SMS Pharmaceuticals ranks 10 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 56.0 out of 100. 1. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 74.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.2/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.4/25 · ROCE 17.8% (year to Mar 2026) · Operating margin 34% · 100% evidence Valuation 7.1/20 · P/E 93.7× · PEG 2.27 · 65% evidence Relative strength 17.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 35.5% · Strength vs NIFTY 500 (same reading) 63.4% · 1 year 137.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.2 + 17.4 + 7.1 + 17.7 = 74.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 74.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.0/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.2/25 · ROCE 31.6% (year to Mar 2026) · Operating margin 40.3% · 76% evidence Valuation 10.4/20 · P/E 74.4× · PEG n/a · 50% evidence Relative strength 11.5/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 43.7% · 1 year 134.5% · 25% evidence · 3 of 9 weeks ahead Exact sum: 32 + 20.2 + 10.4 + 11.5 = 74.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Most evidence points up · 100% evidence 68.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.6/35 · Revenue 21.6% · Profit 35.3% · Operating margin change 10 points · 100% evidence Capital efficiency 19.6/25 · ROCE 22% (year to Mar 2026) · Operating margin 42.6% · 100% evidence Valuation 3.0/20 · P/E 87.2× · PEG 2.88 · 100% evidence Relative strength 17.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 22.7% · Strength vs NIFTY 500 (same reading) 50.5% · 1 year 73.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 28.6 + 19.6 + 3 + 17.5 = 68.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 100% evidence 67.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.1/35 · Revenue 21.9% · Profit 56.3% · Operating margin change 5 points · 100% evidence Capital efficiency 17.1/25 · ROCE 15.1% (year to Mar 2026) · Operating margin 26.4% · 100% evidence Valuation 10.2/20 · P/E 43.1× · PEG 1.84 · 100% evidence Relative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) 18.8% · Strength vs NIFTY 500 (same reading) 44.6% · 1 year 78.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 28.1 + 17.1 + 10.2 + 12.3 = 67.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 90% evidence 65.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.2/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.7/25 · ROCE 11.3% (year to Mar 2026) · Operating margin 13.7% · 100% evidence Valuation 9.3/20 · P/E 27.4× · PEG n/a · 50% evidence Relative strength 14.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 30.8% · Strength vs NIFTY 500 (same reading) 55.8% · 1 year 110.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.2 + 12.7 + 9.3 + 14 = 65.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · losing its lead · Most evidence points up · 100% evidence 65.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.7/35 · Revenue 50.5% · Profit 88.4% · Operating margin change -8 points · 100% evidence Capital efficiency 21.9/25 · ROCE 26.5% (year to Mar 2026) · Operating margin 21.8% · 100% evidence Valuation 10.0/20 · P/E 60.8× · PEG 1.91 · 100% evidence Relative strength 6.4/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.9% · Strength vs NIFTY 500 (same reading) 17.8% · 1 year 29.3% · 100% evidence · 10 of 12 weeks ahead Exact sum: 26.7 + 21.9 + 10 + 6.4 = 65 · What this means: Earnings are strong; relative strength in its sector is -3.9% and the one-year return is 29.3%. 7. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Evidence leans up · 93% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.6/35 · Revenue 37.4% · Profit 100% · Operating margin change -2 points · 100% evidence Capital efficiency 12.2/25 · ROCE 10.9% (year to Mar 2026) · Operating margin 26.8% · 100% evidence Valuation 12.6/20 · P/E 53.8× · PEG 1.42 · 65% evidence Relative strength 14.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 43.4% · Strength vs NIFTY 500 (same reading) 69% · 1 year 161.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.6 + 12.2 + 12.6 + 14.7 = 64.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 75% evidence 63.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% (year to Mar 2026) · Operating margin 16.5% · 100% evidence Valuation 10.4/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 52.4% · 1 year 109.9% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 10.4 + 11.9 = 63.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 93% evidence 58.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.2/35 · Revenue 15.5% · Profit 31.1% · Operating margin change 1 points · 100% evidence Capital efficiency 15.8/25 · ROCE 19.6% (year to Mar 2026) · Operating margin 28.2% · 100% evidence Valuation 4.5/20 · P/E 100.7× · PEG 3.55 · 65% evidence Relative strength 17.8/20 · Strength vs its industry (price vs its 52-week average, weekly) 29.5% · Strength vs NIFTY 500 (same reading) 57.9% · 1 year 107.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.2 + 15.8 + 4.5 + 17.8 = 58.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. SMS Pharmaceuticals Ltd this page SMSPHARMA · breaking out · Evidence leans up · 90% evidence 56.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.5/35 · Revenue 13% · Profit 41% · Operating margin change 1 points · 100% evidence Capital efficiency 11.9/25 · ROCE 13.3% (year to Mar 2026) · Operating margin 21.5% · 100% evidence Valuation 8.3/20 · P/E 38.2× · PEG n/a · 50% evidence Relative strength 15.3/20 · Strength vs its industry (price vs its 52-week average, weekly) 2.4% · Strength vs NIFTY 500 (same reading) 27.1% · 1 year 69.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 20.5 + 11.9 + 8.3 + 15.3 = 56 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · losing its lead · Evidence leans up · 93% evidence 53.0 out of 100 Growth Capital Valuation Relative 12. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · losing its lead · Evidence leans up · 75% evidence 52.6 out of 100 Growth Capital Valuation Relative 13. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · quiet · Evidence leans up · 100% evidence 51.8 out of 100 Growth Capital Valuation Relative 14. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · leader · Evidence leans up · 74% evidence 50.2 out of 100 Growth Capital Valuation Relative 15. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans down · 85% evidence 48.9 out of 100 Growth Capital Valuation Relative 16. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 46.1 out of 100 Growth Capital Valuation Relative 17. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.0 out of 100 Growth Capital Valuation Relative 18. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Evidence leans down · 78% evidence 40.1 out of 100 Growth Capital Valuation Relative 19. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · quiet · Evidence leans down · 100% evidence 39.1 out of 100 Growth Capital Valuation Relative 20. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 80% evidence 30.9 out of 100 Growth Capital Valuation Relative 21. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 90% evidence 30.8 out of 100 Growth Capital Valuation Relative 22. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · losing its lead · Most evidence points down · 82% evidence 24.9 out of 100 Growth Capital Valuation Relative 23. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 68% evidence 24.8 out of 100 Growth Capital Valuation Relative 24. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 24.5 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to SMS Pharmaceuticals in size? SMS Pharmaceuticals is the 20th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: IOL Chemicals & Pharmaceuticals, Morepen Laboratories and Supriya Lifescience. Just below it: Solara Active Pharma Sciences, Hikal and Windlas Biotech. ### Pharma - API & CRAMS companies close in size 1. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) ₹5,569 crore 2. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) ₹5,062 crore 3. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) ₹4,948 crore 4. SMS Pharmaceuticals Ltd ₹4,465 crore 5. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) ₹3,157 crore 6. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) ₹2,751 crore 7. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) ₹2,041 crore [All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies) ### Companies close in size in other industries 1. [Mastek Ltd](https://www.sectoralpha.in/stocks/mastek-ltd) ₹4,476 crore · IT - Software 2. [Shakti Pumps (India) Ltd](https://www.sectoralpha.in/stocks/shakti-pumps-indialtd) ₹4,471 crore · Solar Pumps 3. SMS Pharmaceuticals Ltd ₹4,465 crore 4. [Energy Infrastructure Trust](https://www.sectoralpha.in/stocks/energy-infrastructure-trust) ₹4,465 crore 5. [Aditya Birla Fashion & Retail Ltd](https://www.sectoralpha.in/stocks/aditya-birla-fashion-retail-ltd) ₹4,459 crore · Textiles - Readymade Apparel ## What else do people ask about SMS Pharmaceuticals? ### What is SMS Pharmaceuticals's share price today? SMS Pharmaceuticals Ltd's share price is ₹476.80, +69.1% over the past year. The whole company is worth ₹4,466 Cr on the market. In the last 52 weeks it traded between ₹282 to ₹517; today it is 83% of the way up from the low, 19.8% above its 200-day average (as of 18 November 2026). ### What were SMS Pharmaceuticals's latest quarterly results? SMS Pharmaceuticals Ltd reported revenue of ₹316 Cr and net profit of ₹40.0 Cr for the Sep 2026 quarter. Revenue rose 30.6% and profit rose 60.0% compared with a year earlier. Earnings per share were ₹4.26. The operating margin was 21.5%, 1.7 percentage points higher than a year earlier (as of 18 November 2026). ### What is SMS Pharmaceuticals's market cap? SMS Pharmaceuticals Ltd's market capitalisation is ₹4,466 Cr at a share price of ₹476.80. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is SMS Pharmaceuticals performing? SMS Pharmaceuticals Ltd's share price has been rising for 61 weeks. In its latest quarter, revenue rose 30.6% and profit rose 60.0% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 14 weeks running (as of 18 November 2026). ### Will SMS Pharmaceuticals's share price go up? This page does not forecast SMS Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹476.80, and it has been rising for 61 weeks. Its P/E of 38.2× is higher than 86% of its own last 11 years (as of 18 November 2026). ### Does SMS Pharmaceuticals have too much debt? SMS Pharmaceuticals Ltd has a moderate amount of debt: its debt is 0.46× its equity, and its operating profit is 8 times its interest bill. FY26 borrowings were ₹365 Cr against equity of ₹785 Cr. Keep that borrowing in mind when reading the returns on this page (as of 18 November 2026). ### Where is SMS Pharmaceuticals in its business cycle? SMS Pharmaceuticals Ltd's FY26 operating margin was 19.4%, against a 14-year range of 10.5% to 24.4%. The latest quarter was 21.5%, near the top of its own range. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the SMS Pharmaceuticals story? The main question: the share price moved +69.1% in a year while yearly earnings per share moved +39.6%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is SMS Pharmaceuticals a stock worth studying right now? What the numbers show: SMS Pharmaceuticals Ltd's share price has risen faster than its earnings: +69.1% in a year, against +39.6% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ### Is there a SMS Pharmaceuticals share price forecast for 2026? What management itself guided: FY27 revenue growth and operating margin to exceed 15% and 20% respectively. ### Where does this page get SMS Pharmaceuticals' management information? From SMS Pharmaceuticals' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. ## Lists - Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india - Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india This is research, not advice. We’re not SEBI-registered.